Indications for: NEXLIZET

An adjunct to diet and maximally tolerated statin therapy, in adults with heterozygous familial hypercholesterolemia or established atherosclerotic cardiovascular disease who require additional lowering of LDL-C.

Limitations of Use:

The effect on cardiovascular morbidity and mortality has not been determined.

Adult Dosage:

Swallow whole. 180mg/10mg once daily. After initiation, assess lipid levels within 8–12 weeks. Concomitant bile acid sequestrants: give Nexlizet either ≥2hrs before or ≥4hrs after.

Children Dosage:

Not established.

NEXLIZET Warnings/Precautions:

Hyperuricemia. Assess serum uric acid as clinically indicated. History of gout. Increased risk for tendon rupture/injury (esp. >60yrs, in those taking corticosteroid or fluoroquinolone drugs, renal failure, previous tendon disorders); consider discontinuing if joint pain, swelling, or inflammation develop. History of tendon disorders/rupture: consider alternative therapy. Elderly. Moderate or severe hepatic (Child-Pugh B or C): not recommended. Severe renal impairment (eGFR <30mL/min/1.73 m2). ESRD on dialysis. Pregnancy, nursing mothers: not recommended.

NEXLIZET Classification:

Adenosine triphosphate-citrate lyase (ACL) inhibitor + cholesterol absorption inhibitor.

NEXLIZET Interactions:

Avoid concomitant simvastatin >20mg or pravastatin >40mg. Concomitant cyclosporine increases ezetimibe and cyclosporine levels; monitor. Concomitant use with fibrates (except fenofibrate): not recommended. Concomitant use with fenofibrate: consider alternative therapy if cholelithiasis is suspected. Antagonized by cholestyramine (see Adult dose).

Adverse Reactions:

Upper respiratory tract infection, muscle spasms, hyperuricemia, back pain, abdominal pain or discomfort, bronchitis, pain in extremity, anemia, elevated liver enzymes, diarrhea, arthralgia, sinusitis, fatigue, influenza; BPH, atrial fibrillation, hypersensitivity reactions (ezetimibe).

Generic Drug Availability:


How Supplied:

Tabs—30, 90